Business Wire7h
FDA Approves Genentech’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...
Smart patch combines real-time health monitoring and drug delivery
A DGIST research team, led by Professor Kyung-In Jang, has developed a smart patch capable of real-time biometric signal ...
Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...
Insight News1d
Attorney General Keith Ellison secures $35 Novo Nordisk insulin for Minnesotans
For five years, insulin manufacturer Novo Nordisk agrees to cap out-of-pocket cost of its insulin treatments at $35 per month, and provide free insulin to the neediest Minnesotans.
Awaiting Trump’s abortion pill posture
President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...
Subcutaneous Drug Delivery Devices Market To Reach USD 56.95 Billion By 2032, Growing At A CAGR Of 7.07% - SNS Insider
Subcutaneous Drug Delivery Devices market Growth Fueled by Chronic Diseases and Technological Innovation Akash Anand SNS Insider Pvt. Ltd 415-230-0044 email us here Visit us on social media: Facebook ...
PharmiWeb12d
Glp-1 Analogues Market Share to Exceed USD 606.3 Billion by 2034
Glp-1 Analogues Market OverviewThe Glp analogues market size is expected to be worth USD 606.3 billion by 2034.The target market was valued at USD 45.3 billion in 2024.The market is projected to grow ...
Yahoo News13d
The FDA is about to make weight-loss drugs a lot harder to get
For now, her doctor is going to switch her over to compounded semaglutide — the active pharmaceutical ingredient in Ozempic ...
Peripheral Arterial Disease Pipeline, Clinical Trials, Emerging Drugs Approvals And Companies Delveinsight
.Semaglutide: Novo Nordisk Semaglutide is a long-acting oral GLP-1 analogue being developed and investigated by Novo Nordisk. The drug is currently being evaluated under Phase III clinical trial for ...